Hemab Therapeutics Holdings Inc

COAG

Healthcare|Biotechnology|USA

$38.09

+0.83 (+2.23%)

About

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Stock Price

+12.0%(1Y)

Pipeline Summary

8 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 4Active: 1Completed: 2Unknown: 1

Active Trials (5)

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852Von Willebrand Disease (VWD)

Phase 1Phase 2Recruiting

Enrollment: 108 participants

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

NCT06211634Glanzmann Thrombasthenia

Phase 1Phase 2Active

Enrollment: 57 participants

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT04398628Hematologic Disorder

Recruiting

Enrollment: 3,000 participants

A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

NCT07347249Congenital Factor VII Deficiency

Phase 2Recruiting

Enrollment: 18 participants

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT06610201Von Willebrand Disease (VWD)

Recruiting

Enrollment: 200 participants

BioScore

4.4/10

Cautious